Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study
Abstract Background CD19-directed chimeric antigen receptor T-cell therapy (CART) has improved outcomes for relapsed/refractory non-Hodgkin lymphoma (R/R NHL). However, patients with high-risk molecular features, such as double-expressor lymphoma (DEL+), characterized by concurrent MYC and BCL-2 pro...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2025-11-01
|
| Ráidu: | Journal of Translational Medicine |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12967-025-07281-w |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|